Dr. Jing-Yi Chern, MD

Dr. Chern practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Chern's NPI, 1093031676, was assigned on April 8, 2010. Dr. Chern graduated from USF Health Morsani College of Medicine in 2010. Dr. Chern holds Florida license ME133394.

Dr. Chern's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Chern's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Chern is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Chern to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chern practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Chern's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Chern is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Chern's licenses on file in 2 states: Florida and New York.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Chern treats.

CMS data shows 89 Medicare services from Dr. Chern across 2 procedure codes in 2024, all of them office visits, for 84 Medicare patients. Medicare paid $8,591 for them.

CMS counts 84 Medicare patients who saw Dr. Chern in 2024. The largest group is 65 to 74, with 55 patients. 75% of them have high cholesterol, and 68% have high blood pressure. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chern's median patient age at 64, with 99% women.

In 2024, Dr. Chern wrote 29 Medicare Part D claims for 23 patients. 76% of them were for generic drugs. CMS names the drug for 18 of them, across 1 drug with 11 or more claims each, at $140 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Chern for performance year 2024, reported as part of a group. Dr. Chern accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 11 procedures of removal of the uterus by Dr. Chern, more than 85% of the clinicians it reports for that procedure.

Dmand AI links 18 papers to Dr. Chern, published from 2015 to 2025. 2016 was the busiest year, with 3. The most frequent topics are Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Ovarian Epithelial. Dr. Chern has published most often in Gynecol Oncol. Dr. Chern's most frequent co-authors are Melissa Kristen Frey, MD, Mian Mohammed Khuram Shahzad, MD, PhD and Robert M. Wenham, MD.

Dmand AI links Dr. Chern to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Fallopian Tube Diseases and Fallopian Tube Neoplasms.

CMS Open Payments shows 61 general payments to Dr. Chern from 9 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 55% of the total. AstraZeneca Pharmaceuticals LP paid the most, $28,196.

Dr. Chern graduated from USF Health Morsani College of Medicine in 2010. Dr. Chern is a member of ASCO, Florida Society of Clinical Oncology and Society of Gynecologic Oncology.

Dr. Chern is in network with 9 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.